Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. S3.1-12. Lee M, Saver JL, Chang B, et al. Presence of baseline prehyper- tension and risk of incident stroke: a meta-analysis. Neurology. 2011;77:1330 7. S3.1-13. Shen L, Ma H, Xiang M-X, et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol. 2013;112:266 71. S3.1-14. Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analy- sis. Ann Intern Med. 2015;162:184 91. S3.1-15. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at differ- ent baseline and achieved blood pressure levels overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296 304. S3.1-16. Wang S, Wu H, Zhang Q, et al. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general popu- lation: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168:4857 60. S3.1-17. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S3.1-18. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393 404. S3.1-19. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbid- ity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995 1003. S3.1-20. Wald DS, Law M, Morris JK, et al. 